Clinical Trial Update: 506U78 in Treating Patients With Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on the agent 506U78 for various lymphomas; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Angioimmunoblastic T-cell Lymphoma
• Cutaneous T-cell Lymphoma
• Mycosis Fungoides
• Sezary Syndrome
• Small Intestine Lymphoma
• T-cell Leukemia Lymphoma

Drugs mentioned

• 506U78

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma | Phase 2 | Status: COMPLETED